TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05352633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive BP Arm
Description: Participants in the Intensive BP treatment group have a goal of SBP \<120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals: Angiotension converting enzyme (ACE)-inhibitors;Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard BP Arm
Description: Participants in the Standard BP treatment group have a goal of SBP \<140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
Study: NCT04626401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forearm immobilization
Description: Two days of forearm immobilization

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Forearm immobilization
Description: Two days of forearm immobilization
Study: NCT05054452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiographic assessment
Description: At baseline before standardized volume expansion, a first set of echocardiographic measurements will be performed. Then, we will perform 15-second end-expiratory and end-inspiratory occlusions. Occlusions will be separated by 1 minute to allow the cardiac index to return to its baseline value. A last set of measurements will be performed after fluid administration. Ventilatory settings and other treatments will remain unchanged during the study period.
Study: NCT05867589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga/18F-FAPI-04
Description: Subjects will receive one injection of 68Ga/18F-FAPI-04 (0.1\~0.15mCi/Kg), a PET radiopharmaceutical selective for fibroblast activation protein. 68Ga/18F-FAPI-04 injection will be followed by a 10 ml saline flush.
Study: NCT06065085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile education
Description: The study was conducted as a randomized controlled trial with 134 individuals with hypertension (68 experimental, 66 controlled) who applied a university hospital. The data were collected by Patient Information Form, Healthy Lifestyle Behaviour Scale II, EQ-5D General Quality of Life Scale, Mindful Attention Awareness Scale and Percieved Stress Scale were used. An education application was installed on the mobile phones of the experimental group. Individuals with hypertension were provided with a training for three months through the mobile application. Data collection forms were filled in by the individuals with hypertension in the experimental and controlled groups at the beginning and at the 3rd month via the mobile application.
Study: NCT06180187

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical mallet
Description: elevation of the Schneiderian membrane of maxillary sinus using electrical mallet and place bone graft material to augment the residual alveolar ridge and then place dental implant .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osseo-densification burs
Description: elevation of the Schneiderian membrane of maxillary sinus using osseodensification burs and place bone graft material to augment the residual alveolar ridge and then place dental implant .
Study: NCT04696887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele Tai Chi Intervention for Persons Aging with Long-Term Mobility Disabilities
Description: • 8-week Tele Tai Chi intervention, participants will use a tablet or computer to join a small-group, online class (1hr, twice weekly) from home; during each session, participants will exercise as a group along with the pre-recorded video lessons and have the opportunity for social interaction (via video chat) before and after class.
Study: NCT04950296

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group I: L. plantarum UALp-05TM,
Description: One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group II: L. plantarum UALp-05TM,
Description: One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose
Description: One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
Study: NCT06269939

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: STEM
Description: Memory technique training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEM
Description: Memory technique training
Study: NCT04728685

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Traction
Description: Mechanical Traction will be applied to the lumbar region using a traction unit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Traction
Description: Mechanical Traction will be applied to the lumbar region using a traction unit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Traction
Description: Mechanical Traction will be applied to the lumbar region using a traction unit.
Study: NCT04660643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT06244238

Intervention type: OTHER
Intervention: Observational study
Description: Observational study
Study: NCT04731935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sparrow Therapy System
Description: Transcutaneous auricular neurostimulation
Study: NCT06394687

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk Protein Concentrate
Description: Milk Protein Concentrate is a powdered dairy product made by removing most of the water from milk and contains a protein content below 90% on a dry matter basis. The product has been modified where some of the colloidal calcium phosphate component is reduced, which results in the dissociation of some of casein micelles, forming loose sub-micelle structures. This change modifies the digestion behaviour to be significantly faster.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk Protein Concentrate
Description: Milk Protein Concentrate is a powdered dairy product made by removing most of the water from milk and contains a protein content below 90% on a dry matter basis. The product has been modified where some of the colloidal calcium phosphate component is reduced, which results in the dissociation of some of casein micelles, forming loose sub-micelle structures. This change modifies the digestion behaviour to be significantly faster.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micellar Casein Isolate
Description: Micellar casein isolate is a type of protein supplement derived from milk. It belongs to the casein family of proteins, which includes various forms such as micellar casein, casein hydrolysate, and caseinates. During digestion micellar casein coagulates with both gastric acidification and enzymatic hydrolysis by pepsin, forming large stable curds which slow gastric emptying and provide a slower absorption of amino acids over time.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micellar Casein Isolate
Description: Micellar casein isolate is a type of protein supplement derived from milk. It belongs to the casein family of proteins, which includes various forms such as micellar casein, casein hydrolysate, and caseinates. During digestion micellar casein coagulates with both gastric acidification and enzymatic hydrolysis by pepsin, forming large stable curds which slow gastric emptying and provide a slower absorption of amino acids over time.
Study: NCT06040983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FR-101 Chest Dressing
Description: Subject will receive FR-101 chest dressing and be instructed to use the product on the target skin area accepted radiation therapy once every 2 days, taking care of avoiding applications from 1 to 4 h before treatment to prevent Build-up effect. If the application time is longer than the recommendation, discomfort may happen depending on subject's condition.
Study: NCT04481997

Intervention type: OTHER
Intervention: Exposure to Anti-thrombotic treatment agents and glucose lowering therapy
Description: Exposure to Anti-thrombotic treatment agents and glucose lowering therapy
Study: NCT04651387

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ozonized oil (HOO
Description: In addition to the routine standard treatments for COVID-19, in the intervention group, combined use of HOO capsules and HOO oropharyngeal and nasal spray will be administered 3 times per day (after breakfast, lunch, dinner, possibly with a delay of one hour from the routine treatment) and will be prescribed for 2 weeks (14 days).~Posology: 3 HOO capsules plus 3 HOO intranasal administrations for each naris plus 3 HOO oropharyngeal administrations.
Study: NCT05985460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention: motion-sensor video game
Description: The experimental arm is a 1-2 mins motion-sensoring video game, which can accommodate 1-4 individuals, engaging their entire bodies in the physical motions involved. It aims to increase PA intention by increasing their motivation, as well as personal and family well-being by increasing the interaction with family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: mobile APP game (without motion-sensoring)
Description: The placebo arm is a 1-2 mins mobile app game, which allows 1-4 participants to play together with a duration of 1-2 minutes. It aims to increase participants' family and personal well-being by increasing the interaction of family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).
Study: NCT05052931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel combined with oxaliplatin and S-1
Description: Nab-paclitaxel 100mg/m\^2, D1, Q3W; oxaliplatin 85 mg/m\^2, D1, Q3W; S-1 60 mg/m\^2, D1-14, Q3W; Neoadjuvant chemotherapy 2 cycles, followed by surgery, continue to receive 6 cycles of adjuvant chemotherapy.
Study: NCT05721508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined physical and cognitive program
Description: All participants will complete 12-week training sessions combining physical and cognitive activities, with two 1-hour sessions per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined physical and cognitive program
Description: All participants will complete 12-week training sessions combining physical and cognitive activities, with two 1-hour sessions per week.
Study: NCT05282745

Intervention type: OTHER
Intervention: Follow-up
Description: Participants will be followed up at 6, 12 and 24 months with HPV viral load tests, Thinprep cytologic tests (TCT) and vaginal secretion tests.
Study: NCT05721508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined physical and cognitive program
Description: All participants will complete 12-week training sessions combining physical and cognitive activities, with two 1-hour sessions per week.
Study: NCT04704479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Russian current
Description: For application of Russian current, 2 channels with 2 electrodes each will positioned on the oblique muscles and rectus abdominis motor points using wet spongy pads to enhance electrical activity. Russian current will be a carrier frequency 2500 Hz with frequency of 5 Hz for 5 minutes of muscular conditioning, 40 Hz for 10 minutes for training of slow contraction muscular fibers and 120 Hz for 5 minutes for training of fast contraction muscular fibers with On time (contraction time) 4 secs and Off time (relaxation time) 2 secs. The contraction phase will be at time of patient's expiration while relaxation will be at time of patient's inspiration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMT
Description: patients in both groups trained 3 times a week, each session consisting of 1/2 h by the end of sessions. Initially, repeated cycles of 3 min of work followed by 2 min of rest were conducted (total work- time 18 min). The length of work intervals was increased on a weekly basis while rest periods were shortened to obtain a total work time of 30 min in the last week of the program. The valve opening pressure was continuously monitored at the mouthpiece to ensure the achievement of the target pressure. Patients will receive EMT with a threshold expiratory muscle trainer (Threshold; HealthScan), started breathing through the expiratory port of the threshold muscle trainer at a resistance equal to 15% of their Pemax for 1 week. The resistance will then increase incrementally, 5 to 10% each session, to reach 60% of their baseline Pemax at the end of the first month then continued at 60% of the Pemax, will be adjusted weekly to the new Pemax achieved

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMT
Description: patients in both groups trained 3 times a week, each session consisting of 1/2 h by the end of sessions. Initially, repeated cycles of 3 min of work followed by 2 min of rest were conducted (total work- time 18 min). The length of work intervals was increased on a weekly basis while rest periods were shortened to obtain a total work time of 30 min in the last week of the program. The valve opening pressure was continuously monitored at the mouthpiece to ensure the achievement of the target pressure. Patients will receive EMT with a threshold expiratory muscle trainer (Threshold; HealthScan), started breathing through the expiratory port of the threshold muscle trainer at a resistance equal to 15% of their Pemax for 1 week. The resistance will then increase incrementally, 5 to 10% each session, to reach 60% of their baseline Pemax at the end of the first month then continued at 60% of the Pemax, will be adjusted weekly to the new Pemax achieved
Study: NCT04789356

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adsorbed SARS-CoV-2 (inactivated) vaccine
Description: 600 SU/dose; Two doses separated by 28 days (± 7 days). Intramuscular (deltoid) administration.
Study: NCT05984069

Intervention type: OTHER
Intervention: observational prospective data collection
Description: Collection of data from medical records.
Study: NCT05478031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REM0046127 High Dose
Description: Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~REM0046127 high dose: 1400mg (700mg bid) oral suspension per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REM0046127 Low Dose
Description: Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~REM0046127 low dose: 350mg (175mg bid) oral suspension per day for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~Placebo: placebo oral suspension bid for 28 days and during the 14-days run-in phase
Study: NCT05135715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: 2.0 mg/kg IV every 2 weeks
Study: NCT04813029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Straight leg raise maneuver
Description: With the patient in supine position, one leg is raised to form an angle of at least 45 degrees with the bed. The patient will be asked to keep that position for at least 5 seconds. The maneuver will be repeated after 20-30 seconds. The first adequate maneuver will be considered for the study. Intra-esophageal and intra-abdominal pressure will be analyzed both during baseline and SLR maneuver. Intra-esophageal pressure is measured as peak and mean over 5 seconds, 1 cm and 5 cm above the proximal margin of the LES. Intra-abdominal pressure will be measured as peak and mean over 5 seconds 1 cm below the distal margin of the diaphragm notch.
Study: NCT05499065

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence guided detection of tumor positive margins
Description: To test if the fluorescence can guide the location for fresh frozen section sampling intra-operatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800
Description: Administrate 75mg cetuximab + 15mg cetuximab-800CW for fluorescence visualization
Study: NCT05253261

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Preoperative Cone Beam Computed Tomography (CBCT) scan
Description: CBCT scans (Green X, Vatech, Hwaseong, Korea) are carried out prior to cystostomies. The scanning conditions are constant at 200 µm isotropic voxel size with 360° rotation, 94 kV tube voltage, 7.2 mA tube current and 9 s exposure time with a 15 × 8 cm field of view field of view (FOV).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tooth removal and cystostomy
Description: Surgical interventions are carried out in local anaesthesia. If it is deemed that a tooth or teeth included in the odontogenic cyst is of hopeless prognosis, it is removed at the time of cystostomy procedure. During cystostomy a bony window is created to accessthe cyst. The lining of the cyst is opened to accomodate the tube of the decompression appliance. A sample from the lining of the cyst is sent for histologic evaluation to confirm the diagnosis of odontogenic cyst.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompression
Description: The decompression appliances is delivered in the same sitting as the cystostomy. Patients are instructed on how to wear and clean their decompression device and are recalled for clinical examinations.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Postoperative Cone Beam Computed Tomography (CBCT) scan
Description: Postoperative CBCT examination is performed six months into the decompression period using the same scanning conditions as those used for the preoperative CBCT scan.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyst Enucleation
Description: Following the decompression period enucleation of the remaining cyst is carried out in local anaesthesia.
Study: NCT06399497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal manipulation
Description: A high-velocity low-amplitude spinal manipulation at the L5 level will be performance by means of the lumbar roll technique, with the subject in right lateral decubitus.
Study: NCT05755061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GEMS Plus
Description: 12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that exceed the published physical activity guidelines for adults with MS

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GEMS
Description: 12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that meet the published physical activity guidelines for adults with MS
Study: NCT06399497

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: simulated manipulation
Description: Simulated manipulation intervention, in the same position as in the Intervention Group, performance in right lateral decubitus with the left leg flexed and the left foot resting on the right popliteal fossa. Without stretching the paravertebral tissues, the participant will remain for approximately 20 seconds without receiving manual impulse.
Study: NCT05659160

Intervention type: PROCEDURE
Intervention: Endovascular Therapy
Description: Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.
Study: NCT04475705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60.
Study: NCT04995874

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KOKOPlus protein and micronutrient powder
Description: KokoPlus, a complementary food supplement was formulated by using linear programming methodology to improve the protein quality as well as the micronutrient and macronutrient content of commonly consumed traditional complementary (baby) foods in Ghana . It contains soya powder, sugar and oil along with the essential amino acid lysine and a micronutrient mix. It complies with WHO's complementary feeding guidelines, FAO/WHO recommended micronutrient intake (RNI) and the WHO's guidelines for protein and essential amino acid intake for children in the age group of 6 to 24 months. A daily supply of KokoPlus achieves 30% of the total recommended energy, 60% of total protein and 40% of total fat requirements from complementary foods. It also meets 35-55% of minimum intake of essential amino acids and 50-150% RNI based on the total daily requirements.
Study: NCT04871191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m²/week for four consecutive weeks (Week 0, 1, 2 and 3) Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Subcutaneous injection of 162 mg per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Subcutaneous injection of 125 mg per week
Study: NCT06333600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical minoxidil
Description: Therapeutic intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Vitamin D
Description: Therapeutic intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline spray
Description: placebo